[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-334777-en":3,"detail-sidebar-cat-0-en-105":31,"doc-seo-334777-105":81},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":21,"is_downloadable":21,"audit_status":21,"page_count":22,"language":23,"language_code":24,"site_id":25,"html_lang":24,"table_of_contents":26,"faqs":27,"seo_title":28,"seo_description":14,"update_tm":29,"read_time":30,"preview_page_count":4},334777,4810365810221,"Aurora","https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d",8,"Research & Report","Metabolic Rewiring in Cancer: Small Molecule Inhibitors in Colorectal Cancer Therapy","Alterations in cellular metabolism, including dysregulated glycolysis, lipid metabolism, and glutaminolysis under hypoxic, low-nutrient tumor microenvironments, are central hallmarks of cancer. The review emphasizes how interactions among aerobic glycolysis, lipid metabolism, and glutaminolysis support tumorigenesis and progression. It surveys the current landscape of small-molecule inhibitors that target key metabolic pathways and considers their implications for colorectal cancer treatment.","molecules   \nReview  \nMetabolic Rewiring in Cancer: Small Molecule Inhibitors in Colorectal Cancer Therapy  \nDomiziana Masci 1, Michela Puxeddu 2, Romano Silvestri 2 and Giuseppe La Regina 2, *  \nCitation: Masci, D.; Puxeddu, M.; Silvestri, R.; La Regina, G. Metabolic Rewiring in Cancer: Small Molecule Inhibitors in Colorectal Cancer Therapy. Molecules 2024, 29, 2110 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)molecules29092110  \nAcademic Editor: Jiuming He  \nReceived: 15 March 2024  \nRevised: 16 April 2024  \nAccepted: 29 April 2024  \nPublished: 2 May 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Largo Francesco Vito 1, 00168 Rome, Italy; [domiziana.masci@unicatt.it](domiziana.masci@unicatt.it)  \n2 Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy; [michela.puxeddu@uniroma1.it](michela.puxeddu@uniroma1.it) (M.P.); [romano.silvestri@uniroma1.it](romano.silvestri@uniroma1.it) (R.S.)  \n* Correspondence: [giuseppe.laregina@uniroma1.it](giuseppe.laregina@uniroma1.it)  \nAbstract: Alterations in cellular metabolism, such as dysregulation in glycolysis, lipid metabolism, and glutaminolysis in response to hypoxic and low-nutrient conditions within the tumor microenvironment, are well-recognized hallmarks of cancer. Therefore, understanding the interplay between aerobic glycolysis, lipid metabolism, and glutaminolysis is crucial for developing effective metabolism-based therapies for cancer, particularly in the context of colorectal cancer (CRC) . In this regard, the present review explores the complex field of metabolic reprogramming in tumorigenesis and progression, providing insights into the current landscape of small molecule inhibitors targeting tumorigenic metabolic pathways and their implications for CRC treatment.  \nKeywords: metabolism; Warburg effect; lactate dehydrogenase; lipid metabolism; glutaminolysis; cancer; colorectal cancer  \n1. Introduction  \nColorectal cancer (CRC) is the second leading cause of cancer-related death in women and the third most common cause in men, with more than 1.9 million new CRC cases worldwide being estimated in 2020 [1] . CRC risk factors include a combination of genetic, lifestyle, and environmental factors. The age of a patient represents a major risk factor for sporadic CRC, with an increasing incidence rate after 50 years of age [2] . Adenomatous polyposis and Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer) account for the most common familial CRC cases (about 5% of CRC cases) [3–5] . Alcohol consumption [6] and cigarette smoking (3) have been associated with an increased incidence of CRC, whereas daily food consumption has been associated with a small absolute risk [2] . Cholecystectomy [7], orchidectomy [8], and gonadotropin-releasing hormone (GnRH) agonists [9] are also important conditions contributing to CRC development.  \nTreatment for CRC is primarily contingent on the cancer’s stage, reflecting the extent of its progression. The earliest stage of non-metastatic CRC, called stage 0 (i.e., tumor limited to the bowel or local lymph nodes, with no metastatic dissemination to distant organs), and stages I to III are mainly treated with radiotherapy and/or chemotherapy, whereas patients with stage IV CRC (metastatic CRC (mCRC)) are regularly treated with systemic chemotherapy, as it aims to treat cancer cells throughout the body. In addi","cbCaivcnVVEoq8Zs","https://ap.wps.com/l/cbCaivcnVVEoq8Zs","pdf",3519029,7,1,28,"English","en",105,"# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"Why is metabolic reprogramming considered a hallmark of cancer in this review?\",\"answer\":\"The review links cancer to dysregulated metabolism, particularly aerobic glycolysis, lipid metabolism, and glutaminolysis in response to hypoxic and low-nutrient tumor microenvironments.\"},{\"question\":\"What is the main focus regarding colorectal cancer (CRC) therapy?\",\"answer\":\"It examines small-molecule inhibitors that target tumorigenic metabolic pathways and discusses their implications for CRC treatment.\"},{\"question\":\"Which CRC risk factors are highlighted in the introduction?\",\"answer\":\"The introduction notes genetic factors, lifestyle factors, and environmental influences, including age, familial syndromes such as adenomatous polyposis and Lynch syndrome, and habits like alcohol consumption and cigarette smoking.\"}]","Metabolic Rewiring in Cancer: Small Molecule Inhibitors in Colorectal Cancer Therapy | PDF",1790008353,71,{"code":4,"msg":5,"data":32},[33,38,43,48,53,58,62,65,70,73,77],{"id":21,"doc_module":4,"doc_module_name":34,"category_name":35,"show_sort_weight":36,"slug":37},"Document","Story & Novel",90,"story-novel",{"id":39,"doc_module":4,"doc_module_name":34,"category_name":40,"show_sort_weight":41,"slug":42},2,"Literature",80,"literature",{"id":44,"doc_module":4,"doc_module_name":34,"category_name":45,"show_sort_weight":46,"slug":47},4,"Exam",70,"exam",{"id":49,"doc_module":4,"doc_module_name":34,"category_name":50,"show_sort_weight":51,"slug":52},5,"Comic",60,"comic",{"id":54,"doc_module":4,"doc_module_name":34,"category_name":55,"show_sort_weight":56,"slug":57},6,"Technology",50,"technology",{"id":20,"doc_module":4,"doc_module_name":34,"category_name":59,"show_sort_weight":60,"slug":61},"Healthcare",40,"healthcare",{"id":11,"doc_module":4,"doc_module_name":34,"category_name":12,"show_sort_weight":63,"slug":64},30,"research-report",{"id":66,"doc_module":4,"doc_module_name":34,"category_name":67,"show_sort_weight":68,"slug":69},9,"Religion & Spirituality",20,"religion-spirituality",{"id":68,"doc_module":4,"doc_module_name":34,"category_name":71,"show_sort_weight":68,"slug":72},"World Cup","world-cup",{"id":74,"doc_module":4,"doc_module_name":34,"category_name":75,"show_sort_weight":74,"slug":76},10,"Lifestyle","lifestyle",{"id":78,"doc_module":4,"doc_module_name":34,"category_name":79,"show_sort_weight":49,"slug":80},19,"General","general",{"code":4,"msg":82,"data":83},"ok",{"site_id":25,"language":24,"slug":84,"title":13,"keywords":85,"description":14,"schema_data":86,"social_meta":140,"head_meta":142,"extra_data":144,"updated_unix":145},"metabolic-rewiring-in-cancer-small-molecule-inhibitors-in-colorectal-cancer-therapy","",{"@graph":87,"@context":139},[88,102,122],{"@type":89,"itemListElement":90},"BreadcrumbList",[91,95,97,100],{"item":92,"name":93,"@type":94,"position":21},"https://docshare.wps.com","Home","ListItem",{"item":96,"name":34,"@type":94,"position":39},"https://docshare.wps.com/document/",{"item":98,"name":12,"@type":94,"position":99},"https://docshare.wps.com/document/research-report/",3,{"item":101,"name":13,"@type":94,"position":44},"https://docshare.wps.com/document/metabolic-rewiring-in-cancer-small-molecule-inhibitors-in-colorectal-cancer-therapy/334777/",{"url":101,"name":13,"@type":103,"image":104,"author":109,"headline":13,"publisher":111,"fileFormat":114,"inLanguage":24,"description":14,"dateModified":115,"datePublished":116,"encodingFormat":114,"isAccessibleForFree":117,"interactionStatistic":118},"DigitalDocument",{"url":105,"@type":106,"width":107,"height":108},"https://docshare.wps.com/thumbnails/metabolic-rewiring-in-cancer-small-molecule-inhibitors-in-colorectal-cancer-therapy/334777.png","ImageObject",300,407,{"name":9,"@type":110},"Person",{"url":92,"name":112,"@type":113},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":119,"interactionType":120,"userInteractionCount":20},"InteractionCounter",{"@type":121},"ViewAction",{"@type":123,"mainEntity":124},"FAQPage",[125,131,135],{"name":126,"@type":127,"acceptedAnswer":128},"Why is metabolic reprogramming considered a hallmark of cancer in this review?","Question",{"text":129,"@type":130},"The review links cancer to dysregulated metabolism, particularly aerobic glycolysis, lipid metabolism, and glutaminolysis in response to hypoxic and low-nutrient tumor microenvironments.","Answer",{"name":132,"@type":127,"acceptedAnswer":133},"What is the main focus regarding colorectal cancer (CRC) therapy?",{"text":134,"@type":130},"It examines small-molecule inhibitors that target tumorigenic metabolic pathways and discusses their implications for CRC treatment.",{"name":136,"@type":127,"acceptedAnswer":137},"Which CRC risk factors are highlighted in the introduction?",{"text":138,"@type":130},"The introduction notes genetic factors, lifestyle factors, and environmental influences, including age, familial syndromes such as adenomatous polyposis and Lynch syndrome, and habits like alcohol consumption and cigarette smoking.","https://schema.org",{"og:url":101,"og:type":141,"og:title":13,"og:site_name":112,"og:description":14},"article",{"robots":143,"canonical":101},"index,follow",{"doc_id":7,"site_id":25},1790196736]